BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 33672644)

  • 1. Systemic Inflammation and Tumour-Infiltrating T-Cell Receptor Repertoire Diversity Are Predictive of Clinical Outcome in High-Grade B-Cell Lymphoma with
    Olschewski V; Witte HM; Bernard V; Steinestel K; Peter W; Merz H; Rieken J; Biersack H; von Bubnoff N; Feller AC; Gebauer N
    Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33672644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-Grade B-Cell Lymphoma (HGBL) with
    Tsai CC; Su YC; Bamodu OA; Chen BJ; Tsai WC; Cheng WH; Lee CH; Hsieh SM; Liu ML; Fang CL; Lin HT; Chen CL; Yeh CT; Lee WH; Ho CL; Lai SW; Tzeng HE; Hsieh YY; Chang CL; Zheng YM; Liu HW; Yen Y; Whang-Peng J; Chao TY
    Cancers (Basel); 2021 Mar; 13(7):. PubMed ID: 33807449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Double-Hit Gene Expression Signature Defines a Distinct Subgroup of Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma.
    Ennishi D; Jiang A; Boyle M; Collinge B; Grande BM; Ben-Neriah S; Rushton C; Tang J; Thomas N; Slack GW; Farinha P; Takata K; Miyata-Takata T; Craig J; Mottok A; Meissner B; Saberi S; Bashashati A; Villa D; Savage KJ; Sehn LH; Kridel R; Mungall AJ; Marra MA; Shah SP; Steidl C; Connors JM; Gascoyne RD; Morin RD; Scott DW
    J Clin Oncol; 2019 Jan; 37(3):190-201. PubMed ID: 30523716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutational landscape of high-grade B-cell lymphoma with
    Künstner A; Witte HM; Riedl J; Bernard V; Stölting S; Merz H; Olschewski V; Peter W; Ketzer J; Busch Y; Trojok P; Bubnoff NV; Busch H; Feller AC; Gebauer N
    Haematologica; 2022 Aug; 107(8):1850-1863. PubMed ID: 34788985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The role of translocations involving c-MYC/8q24, BCL2/18q21 and/or BCL6/3q27 genes in patients with follicular lymphoma. Retrospective analysis of single - centre data].
    Misyurina AE; Kravchenko SK; Kovrigina AM; Magomedova AU; Plastinina LV; Obukhova TN; Misyurin AV; Misyurin VA; Grebenuk LA; Babaeva FE; Baryakh EA; Vorobiev AI
    Ter Arkh; 2019 Jul; 91(7):52-62. PubMed ID: 32598736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patients with double/triple copy number gains on C-MYC, BCL2, and/or BCL6 treated with standard chemotherapy have a similarly poor prognosis than those with high-grade B cell lymphoma with C-MYC and BCL2 and/or BCL6 rearrangements: a single-center experience on a consecutive cohort of large B cell lymphomas.
    Willenbacher E; Willenbacher W; Weger R; Dominik W; Manzl C; Brunner A
    Ann Hematol; 2020 Sep; 99(9):2125-2132. PubMed ID: 32613279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exhaustion of tumour-infiltrating T-cell receptor repertoire diversity is an age-dependent indicator of immunological fitness independently predictive of clinical outcome in Burkitt lymphoma.
    Rieken J; Bernard V; Witte HM; Peter W; Merz H; Olschewski V; Hertel L; Lehnert H; Biersack H; von Bubnoff N; Feller AC; Gebauer N
    Br J Haematol; 2021 Apr; 193(1):138-149. PubMed ID: 32945554
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-grade B-cell lymphoma (HGBL)-NOS is clinicopathologically and genetically more similar to DLBCL/HGBL-DH than DLBCL.
    Li S; Qiu L; Xu J; Lin P; Ok CY; Tang G; McDonnell TJ; James You M; Khanlari M; Miranda RN; Medeiros LJ
    Leukemia; 2023 Feb; 37(2):422-432. PubMed ID: 36513804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transformation of Follicular Lymphoma to a High-Grade B-Cell Lymphoma With MYC and BCL2 Translocations and Overlapping Features of Burkitt Lymphoma and Acute Lymphoblastic Leukemia: A Case Report and Literature Review.
    Bischin AM; Dorer R; Aboulafia DM
    Clin Med Insights Blood Disord; 2017; 10():1179545X17692544. PubMed ID: 28579851
    [TBL] [Abstract][Full Text] [Related]  

  • 10. De novo acute lymphoblastic leukemia-like disease of high grade B-cell lymphoma with
    Uchida A; Isobe Y; Uemura Y; Nishio Y; Sakai H; Kato M; Otsubo K; Hoshikawa M; Takagi M; Miura I
    BMC Clin Pathol; 2017; 17():21. PubMed ID: 29151814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment strategy for high-grade B-cell lymphoma].
    Maruyama D
    Rinsho Ketsueki; 2018; 59(10):2109-2116. PubMed ID: 30305516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-intensity chemotherapy improved the prognosis of patients with high-grade B-cell lymphoma.
    Chen Y; Cai Q; Chang Y; Zhang M; Li Z
    Front Immunol; 2022; 13():1047115. PubMed ID: 36618391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical significance of 'double-hit' and 'double-expression' lymphomas.
    Ma Z; Niu J; Cao Y; Pang X; Cui W; Zhang W; Li X
    J Clin Pathol; 2020 Mar; 73(3):126-138. PubMed ID: 31615842
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-grade B-Cell lymphoma with
    Rogers TS; Gardner JA; Devitt KA
    Autops Case Rep; 2019; 9(3):e2019090. PubMed ID: 31440479
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction treatment in high-grade B-cell lymphoma with a concurrent
    Zeremski V; Kropf S; Koehler M; Gebauer N; McPhail ED; Habermann T; Schieppati F; Mougiakakos D
    Front Oncol; 2023; 13():1188478. PubMed ID: 37546419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-grade B-cell lymphoma with a quadruple-hit genetic profile including concurrent MYC, BCL2, BCL6, and CCND1 gene rearrangements.
    Gagnon MF; Meyer RG; Weaver EJ; Wood AJ; Dupuy DA; Menachery SJ; Shi M; Baughn LB; Ketterling RP; Peterson JF
    Lab Med; 2024 Mar; ():. PubMed ID: 38522075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Double-hit B-cell lymphomas with BCL6 and MYC translocations are aggressive, frequently extranodal lymphomas distinct from BCL2 double-hit B-cell lymphomas.
    Pillai RK; Sathanoori M; Van Oss SB; Swerdlow SH
    Am J Surg Pathol; 2013 Mar; 37(3):323-32. PubMed ID: 23348205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A large single-institution retrospective analysis of aggressive B-cell lymphomas according to the 2016/2017 WHO classification.
    Jesionek-Kupnicka D; Braun M; Robak T; Kuncman W; Kordek R
    Adv Clin Exp Med; 2019 Oct; 28(10):1359-1365. PubMed ID: 31518494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bright CD38 Expression by Flow Cytometric Analysis Is a Biomarker for Double/Triple Hit Lymphomas with a Moderate Sensitivity and High Specificity.
    Alsuwaidan A; Pirruccello E; Jaso J; Koduru P; Garcia R; Krueger J; Doucet M; Chaudhry R; Fuda F; Chen W
    Cytometry B Clin Cytom; 2019 Sep; 96(5):368-374. PubMed ID: 30734478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real world data on young patients with high-risk diffuse large B-cell lymphoma treated with R-CHOP or R-CHOEP - MYC, BCL2 and BCL6 as prognostic biomarkers.
    Pedersen MØ; Gang AO; Brown P; Pedersen M; Knudsen H; Nielsen SL; Poulsen T; Wirenfeldt Klausen T; Høgdall E; Nørgaard P
    PLoS One; 2017; 12(10):e0186983. PubMed ID: 29088292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.